Navigation Links
Vanda Pharmaceuticals to Announce Third Quarter 2013 Financial Results on November 7, 2013
Date:10/21/2013

WASHINGTON, Oct. 21, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced it will release results for the third quarter of 2013 on Thursday, November 7, 2013, before the market opens.

The Company will host a conference call at 10:00 AM ET on Thursday, November 7, 2013, during which Vanda management will discuss the financial results.  To participate in the conference call, please dial 1-888-895-5271 (domestic) or 1-847-619-6547 (international) and use passcode 35919679.

The conference call will be broadcast simultaneously and archived on the Company's website, www.vandapharma.com.  Investors should go to the website at least 15 minutes early to register, download, and install any necessary audio software.

A replay of the call will be available on Thursday, November 7, 2013, beginning at 12:00 PM ET and will be accessible until Thursday, November 14, 2013, at 5:00 PM ET.  The replay call-in number is 1-888-843-7419 for domestic callers and 1-630-652-3042 for international callers.  The passcode number is 35919679.

ABOUT VANDA PHARMACEUTICALS INC.:    
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders.  For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com.  

Investor Contact:   
Chad Rubin
Vice President
The Trout Group
(646) 378-2947
crubin@troutgroup.com


'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Vanda Pharmaceuticals Inc. Proposes Public Offering of Common Stock
2. UPCOMING DEADLINE: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Vanda Pharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of August 24, 2013 to Seek a Lead Plaintiff Position
3. Vanda Pharmaceuticals Reports Second Quarter 2013 Results
4. Vanda Pharmaceuticals to Announce Second Quarter 2013 Financial Results on July 31, 2013
5. Vanda Pharmaceuticals to Participate in Upcoming Investor Conferences
6. Vanda Pharmaceuticals, Inc. Sued by Investor
7. Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
8. Vanda Presents Data From Tasimelteon Phase III Studies In Non-24-Hour Disorder
9. Vanda Pharmaceuticals to Present at the Jefferies 2013 Global Healthcare Conference
10. Vanda Announces Submission To FDA Of A New Drug Application For Tasimelteon For The Treatment Of Non-24-Hour Disorder In The Totally Blind
11. Vanda to Present Tasimelteon Non-24 Phase III Data at Two Medical Meetings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Any dentist who has made an implant supported ... Many of them do not even offer this as a ... laboratory costs involved. And those who ARE able to offer ... high cost that the majority of today,s patients would not ... Zadeh , founder of Dental Evolutions Inc. and inventor of ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
(Date:6/23/2016)... 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... America . ... ... ... ...
Breaking Medicine Technology:
(Date:6/25/2016)... D.C. (PRWEB) , ... June 25, 2016 , ... ... discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, ... their work on several important health care topics including advance care planning, healthcare ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... 24, 2016 , ... The Haute Beauty Network, affiliated with ... as a prominent plastic surgeon and the network’s newest partner. , Dr. ... handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands by ...
Breaking Medicine News(10 mins):